Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Retained Earnings (2016 - 2025)

Avanos Medical's Retained Earnings history spans 11 years, with the latest figure at -$36.9 million for Q3 2024.

  • For Q3 2024, Retained Earnings rose 88.66% year-over-year to -$36.9 million; the TTM value through Sep 2024 reached -$36.9 million, up 88.66%, while the annual FY2023 figure was -$314.9 million, 779.61% down from the prior year.
  • Retained Earnings for Q3 2024 was -$36.9 million at Avanos Medical, up from -$37.5 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$28.4 million in Q2 2023 and bottomed at -$325.4 million in Q3 2023.
  • The 5-year median for Retained Earnings is -$42.9 million (2022), against an average of -$164.3 million.
  • The largest annual shift saw Retained Earnings skyrocketed 90.31% in 2023 before it plummeted 908.95% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$315.5 million in 2020, then surged by 89.29% to -$33.8 million in 2021, then dropped by 5.92% to -$35.8 million in 2022, then tumbled by 779.61% to -$314.9 million in 2023, then soared by 88.28% to -$36.9 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Retained Earnings are -$36.9 million (Q3 2024), -$37.5 million (Q2 2024), and -$315.8 million (Q1 2024).